Infection

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Gritstone bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRTS

Retrieved on: 
Saturday, July 20, 2024

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) and certain officers.

Key Points: 
  • NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Public advisory - Unauthorized drug products sold illegally on Quadragen and Advanced Research websites may pose serious health risks

Retrieved on: 
Friday, July 19, 2024

Product: Unauthorized drugs sold on Quadragen and Advanced Research websites associated with the company Quad Inc.

Key Points: 
  • Product: Unauthorized drugs sold on Quadragen and Advanced Research websites associated with the company Quad Inc.
    Issue: Health products – Unauthorized product; Product safety
    What to do: Do not use these products.
  • In addition to the injectable peptide drugs that Health Canada previously warned about, the following drug products were also being illegally sold on the Advanced Research and Quadragen websites and may pose serious health risks:
    Bromantane and omberacetam oral drops promoted as "nootropics" on the company's websites.
  • Original Advisory – June 26, 2024: Unauthorized injectable drug products sold illegally on Quadragen and Advanced Research websites may pose serious health risks
    Health Canada is warning consumers not to buy unauthorized injectable drugs from Quadragen and Advanced Research websites ( www.quadragen.io/ , and www.advancedresearch.bio/) because they may pose serious health risks.
  • Health Canada seized injectable peptides, along with unauthorized bodybuilding drugs , from Quad Inc. At Health Canada's request, the company has stopped advertising and selling unauthorized health products, including taking down its Quadragen and Advanced Research websites.

Healthcare Education Solutions Market size is set to grow by USD 7.31 billion from 2024-2028, Need to address challenges in the healthcare industry through effective medical training boost the market, Technavio

Retrieved on: 
Friday, July 19, 2024

Effective CME programs must align with Healthcare Professionals (HCPs) requirements, address patients' needs, and respond to evolving disease patterns and current healthcare challenges.

Key Points: 
  • Effective CME programs must align with Healthcare Professionals (HCPs) requirements, address patients' needs, and respond to evolving disease patterns and current healthcare challenges.
  • Omnasuris, with partnerships with over 12 State Governments and 10 Medical Councils, offers 209 courses, catering to busy schedules and budgets.
  • The Healthcare Education Solutions market is experiencing significant growth, with companies like Trivantis and Edulence leading the charge.
  • Data quality and access to reliable information sources are essential for effective education in cardiology and other healthcare fields.

Global Sports Medicine Industry Report 2024-2028: 3D Printing's Increasing Role in Sports Medicine - ResearchAndMarkets.com

Retrieved on: 
Friday, July 19, 2024

The "Global Sports Medicine Industry, Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Sports Medicine Industry, Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • This analysis covers innovative devices propelling industry growth as well as market trends and emerging business models that will dominate the sports medicine sector.
  • It highlights the dominating solutions in the sports medicine devices industry, including body reconstruction and body support and recovery devices, as well as companies' business models and recent advances to meet present-day challenges.
  • As a result, it is a key factor driving the growth of sports medicine, with advancements such as 3D printed implants and computer-aided design programs.

ParkOhio Announces Quarterly Dividend

Retrieved on: 
Friday, July 19, 2024

The Board of Directors of Park-Ohio Holdings Corp. (NASDAQ: PKOH) has declared a quarterly cash dividend of $0.125 per share on the common stock outstanding, to be paid on August 16, 2024, to shareholders of record as of the close of business on August 2, 2024.

Key Points: 
  • The Board of Directors of Park-Ohio Holdings Corp. (NASDAQ: PKOH) has declared a quarterly cash dividend of $0.125 per share on the common stock outstanding, to be paid on August 16, 2024, to shareholders of record as of the close of business on August 2, 2024.
  • ParkOhio is a diversified international company providing world-class customers with a supply chain management outsourcing service, capital equipment used on their production lines, and manufactured components used to assemble their products.
  • Headquartered in Cleveland, Ohio, ParkOhio operates approximately 130 manufacturing sites and supply chain logistics facilities worldwide, through three reportable segments: Supply Technologies, Assembly Components and Engineered Products.
  • Risk Factors" included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Why does plague keep plaguing humans?

Retrieved on: 
Friday, July 19, 2024

Before the 20th century, the most-deadly-disease mantle was held in Europe and surrounding areas by the bubonic plague.

Key Points: 
  • Before the 20th century, the most-deadly-disease mantle was held in Europe and surrounding areas by the bubonic plague.
  • However, from the 1960s onwards, cases dropped dramatically, and the bubonic plague is not often considered a modern disease.
  • The bubonic plague, or plague for short, is caused by a bacterium called Yersinia pestis.
  • These insects bite the rats and afterwards may jump and bite a human, injecting the plague bacterium into the lymphatic system of the human.
  • The main symptom of bubonic plague is swollen lymph nodes, usually in the neck, groin, thighs and armpits.

Under control

Addendum to the Guideline on clinical development of vaccines to address clinical trials in immunocompromised individuals

Retrieved on: 
Friday, July 19, 2024

27 Immunocompromised individuals are commonly excluded from clinical trials conducted before the first 28 licensure of new vaccines to avoid confounding interpretation of the immunogenicity and efficacy data.

Key Points: 
    • 27 Immunocompromised individuals are commonly excluded from clinical trials conducted before the first 28 licensure of new vaccines to avoid confounding interpretation of the immunogenicity and efficacy data.
    • 36 In summary, there is a clinical need to generate appropriate evidence to identify appropriate dose 37 regimens for immunocompromised individuals.
    • 1 does not provide 40 detailed guidance on the design of clinical trials to assess the safety, immunogenicity and efficacy of 41 vaccines in immunocompromised individuals.
    • 50 Moreover, this guidance does not address clinical development programmes for vaccines intended only 51 for use in immunocompromised subjects or in specific subgroups of such subjects (i.e.
    • Legal basis and relevant guidelines 56 This guidance should be read in conjunction with the Guideline on clinical evaluation of vaccines 57 (EMEA/CHMP/VWP/164653/05 Rev.
    • 58 Addendum to the Guideline on clinical development of vaccines to address clinical trials in immunocompromised individuals EMA/336761/2024 Page 2/5 60 4.
    • Objectives of clinical trials in immunocompromised individuals 72 In the vast majority of cases, the clinical efficacy of a candidate vaccine will not be evaluated in 73 immunocompromised individuals.
    • Additional safety considerations for clinical trials in immunocompromised individuals should be 155 assessed on a case by case basis (i.e.
    • 157 Addendum to the Guideline on clinical development of vaccines to address clinical trials in immunocompromised individuals EMA/336761/2024 Page 5/5

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Retrieved on: 
Friday, July 19, 2024

Tufts Medical Center, Yale University, and Rhode Island Hospital will conduct the world's first randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients.

Key Points: 
  • Tufts Medical Center, Yale University, and Rhode Island Hospital will conduct the world's first randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients.
  • At least 24, and potentially up to 33, hospitalized patients diagnosed with relapsing babesiosis will be recruited for the study, with interim results anticipated by September, 2025.
  • The Tafenoquine for Babesiosis clinical trial currently enrolling patients is anticipated to shed new light on how best to address the babesiosis treatment needs of this group.
  • The total cumulative accessible market through the end of U.S. patent protection in December 2035, for ARAKODA® (tafenoquine) for babesiosis is approximately 400,000 patients.

Long COVID puzzle pieces are falling into place – the picture is unsettling

Retrieved on: 
Friday, July 19, 2024

Long COVID is a term that describes the constellation of long-term health effects caused by infection with the SARS-CoV-2 virus.

Key Points: 
  • Long COVID is a term that describes the constellation of long-term health effects caused by infection with the SARS-CoV-2 virus.
  • I am a physician scientist, and I have been deeply immersed in studying long COVID since the early days of the pandemic.
  • Over the first half of 2024, a flurry of reports and scientific papers on long COVID added clarity to this complex condition.

How long COVID affects the body

  • In 2020, when the ancestral strain of SARS-CoV-2 was dominant and vaccines were not available, about 10.4% of adults who got COVID-19 developed long COVID.
  • In other words, unvaccinated people were more than twice as likely to develop long COVID.
  • While researchers like me do not yet have concrete numbers for the current rate in mid-2024 due to the time it takes for long COVID cases to be reflected in the data, the flow of new patients into long COVID clinics has been on par with 2022.
  • Estimates for the first year of the pandemic suggests that at least 65 million people globally have had long COVID.
  • It concludes that long COVID is a complex chronic condition that can result in more than 200 health effects across multiple body systems.

A long road ahead

  • Such findings parallel other research showing that the virus persists in various organ systems for months or years after COVID-19 infection.
  • Together, these studies may explain why a SARS-CoV-2 infection years ago could still cause new health problems long after the initial infection.
  • Important progress is also being made in understanding the pathways by which long COVID wreaks havoc on the body.

An ongoing threat

Appili Therapeutics Announces Second Amendment to Arrangement Agreement

Retrieved on: 
Thursday, July 18, 2024

HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a second amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adivir” and together with the Company and Aditxt, the “Parties”) to amend the previously announced arrangement agreement dated April 1, 2024 among the Parties (as amended on July 1, 2024, the “Arrangement Agreement”), pursuant to which Aditxt, through its wholly-owned subsidiary, Adivir, will acquire all of the issued and outstanding Class A common shares of the Company by way of a court-approved plan of arrangement under the Canada Business Corporations Act (the “Transaction”). For further information on the Transaction please see the Company’s news releases dated April 2, 2024 and July 2, 2024, which are available on the Company’s profile on SEDAR+ at www.sedarplus.ca.

Key Points: 
  • For further information on the Transaction please see the Company’s news releases dated April 2, 2024 and July 2, 2024, which are available on the Company’s profile on SEDAR+ at www.sedarplus.ca .
  • Under the Amending Agreement, (a) the Outside Date (as defined in the Arrangement Agreement) was changed from August 30, 2024 to September 30, 2024, (b) the deadline to convene the Company’s special shareholders’ meeting was changed from August 30, 2024 to September 30, 2024, and (c) the deadline for Aditxt to complete the Financing (as defined in the Arrangement Agreement) was changed from August 30, 2024 to September 15, 2024 or such later date as the Parties may agree in writing.
  • This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein.
  • The securities offered have not been registered under the United States Securities Act of 1933, as amended (the “U.S.